Primary angle-closure is the synechial or appositional closure of the anterior chamber angle secondary to multiple mechanisms resulting in raised intraocular pressure and structural changes in the eyes.
Iridotrabecular contact is the hallmark of primary angle-closure and the most commonly identified sign which indicates that treatment is required.
It is defined by at least 180 degrees of iridotrabecular contact together with an elevated intraocular pressure or peripheral anterior synechiae or btoh
Primary angle-closure glaucoma is the presence of glaucomatous optic neuropathy.
Following iridotomy, patients with a residual open angle or a combination of open angle and some peripheral anterior synechiae (PAS) with or without glaucomatous optic neuropathy should be followed at least yearly
Repeat gonioscopy to determine interval changes (eg increased extent of PAS, development of secondary angle-closure from cataract progression and increased lens thickness)
Subsequent follow-up intervals will depend on the clinical findings
Reassess visual function, risk factors [especially gonioscopic changes and intraocular pressure (IOP)], quality of life
Reassess structure and function of the optic nerve
Assess adherence to the treatment plan
Revise management plan, if necessary, and discuss follow-up plan
Indications for more frequent surveillance/follow-up:
Change in health status
IOP above target
Side effect to glaucoma medication
Visual field change
Intervening eye infection (especially for post-operative eyes), surgery, trauma, iritis
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.